drugset / Trial / NCT01367158

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

NCT01367158

Phase 2 Completed 440 enrolled Novartis Vaccines
RandomizedParallel-groupSingle-blindPrevention

Summary

This study will evaluate safety, tolerability, and immunogenicity of a booster dose of a meningococcal vaccine formulation in adolescents.

Timeline

Start
2011-07
Primary completion
2012-01
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MenABCWY Vaccine
Subject Tdap Vaccine Intramuscular
Comparator rMenB Vaccine